Loading...

Eurofins Scientific SE

ERF.PAEURONEXT
Healthcare
Medical - Diagnostics & Research
64.74
2.02(3.22%)
U.S. Market opens in 2h 28m

Eurofins Scientific SE Fundamental Analysis

Eurofins Scientific SE (ERF.PA) shows moderate financial fundamentals with a PE ratio of 23.74, profit margin of 6.51%, and ROE of 11.62%. The company generates $7.2B in annual revenue with moderate year-over-year growth of 6.70%.

Key Strengths

No significant strengths identified.

Areas of Concern

No major concerns flagged.
We analyze ERF.PA's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 36.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
36.7/100

We analyze ERF.PA's fundamental strength across five key dimensions:

Efficiency Score

Weak

ERF.PA struggles to generate sufficient returns from assets.

ROA > 10%
4.32%

Valuation Score

Excellent

ERF.PA trades at attractive valuation levels.

PE < 25
23.74
PEG Ratio < 2
1.79

Growth Score

Excellent

ERF.PA delivers strong and consistent growth momentum.

Revenue Growth > 5%
6.70%
EPS Growth > 10%
32.30%

Financial Health Score

Moderate

ERF.PA shows balanced financial health with some risks.

Debt/Equity < 1
1.53
Current Ratio > 1
1.09

Profitability Score

Weak

ERF.PA struggles to sustain strong margins.

ROE > 15%
11.62%
Net Margin ≥ 15%
6.51%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is ERF.PA Expensive or Cheap?

P/E Ratio

ERF.PA trades at 23.74 times earnings. This indicates a fair valuation.

23.74

PEG Ratio

When adjusting for growth, ERF.PA's PEG of 1.79 indicates fair valuation.

1.79

Price to Book

The market values Eurofins Scientific SE at 3.18 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

3.18

EV/EBITDA

Enterprise value stands at 5.84 times EBITDA. This is generally considered low.

5.84

How Well Does ERF.PA Make Money?

Net Profit Margin

For every $100 in sales, Eurofins Scientific SE keeps $6.51 as profit after all expenses.

6.51%

Operating Margin

Core operations generate 15.62 in profit for every $100 in revenue, before interest and taxes.

15.62%

ROE

Management delivers $11.62 in profit for every $100 of shareholder equity.

11.62%

ROA

Eurofins Scientific SE generates $4.32 in profit for every $100 in assets, demonstrating efficient asset deployment.

4.32%

Following the Money - Real Cash Generation

Operating Cash Flow

Eurofins Scientific SE produces operating cash flow of $1.03B, showing steady but balanced cash generation.

$1.03B

Free Cash Flow

Eurofins Scientific SE produces free cash flow of $396.00M, offering steady but limited capital for shareholder returns and expansion.

$396.00M

FCF Per Share

Each share generates $2.24 in free cash annually.

$2.24

FCF Yield

ERF.PA converts 3.64% of its market value into free cash.

3.64%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

23.74

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

1.79

vs 25 benchmark

P/B Ratio

Price to book value ratio

3.18

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.52

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

1.53

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.09

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.12

vs 25 benchmark

ROA

Return on assets percentage

0.04

vs 25 benchmark

ROCE

Return on capital employed

0.13

vs 25 benchmark

How ERF.PA Stacks Against Its Sector Peers

MetricERF.PA ValueSector AveragePerformance
P/E Ratio23.7427.91 Better (Cheaper)
ROE11.62%687.00% Weak
Net Margin6.51%-45285.00% (disorted) Weak
Debt/Equity1.530.33 Weak (High Leverage)
Current Ratio1.092795.76 Neutral
ROA4.32%-13557.00% (disorted) Weak

ERF.PA outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Eurofins Scientific SE's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

42.27%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

94.43%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

81.70%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ